Literature DB >> 7822240

Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins.

M Ishigami1, S Yamashita, N Sakai, T Arai, K Hirano, H Hiraoka, K Kameda-Takemura, Y Matsuzawa.   

Abstract

High-density lipoprotein (HDL) has been speculated to have an anti-atherogenic function. Many in vitro studies have demonstrated that HDL has the ability to remove cholesteryl ester (CE) from lipid-laden macrophages. However, the effect of alteration in chemical composition and particle diameter on the in vivo function of HDL is unknown. In the study described here, we have isolated the HDL from patients homozygous for cholesteryl ester transfer protein (CETP) deficiency and examined its function in vitro, in order to clarify the anti-atherogenic property of HDL in CETP-deficient subjects. Apolipoprotein (apo) E-free HDL2 from the patients, separated by heparin-Sepharose column chromatography, was rich in CE, poor in triglycerides (TG), and enlarged in size on 4-30% nondenaturing polyacrylamide gradient gel electrophoresis. In contrast, HDL3 from the patients was normal in size and in its chemical composition. First, we examined the effect of HDL on CE accumulation in macrophages. After mouse peritoneal macrophages had been incubated with both acetylated low-density lipoproteins (Ac-LDL) and HDL, cellular CE content was determined by an enzymatic, fluorometric method. Ac-LDL alone induced a 9-fold accumulation of CE. The addition of apo E-free HDL2 and HDL3 from controls and patients' HDL3 prevented CE accumulation in macrophages, while patients' HDL2 had no preventive effect. We next investigated the in vitro ability of HDL to remove cellular CE from lipid-laden macrophages after incubation with Ac-LDL. After loading of macrophages with cholesterol by Ac-LDL, HDL was added to the culture medium and the cellular CE content was measured.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7822240     DOI: 10.1093/oxfordjournals.jbchem.a124516

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  22 in total

Review 1.  Genetic causes of high and low serum HDL-cholesterol.

Authors:  Daphna Weissglas-Volkov; Päivi Pajukanta
Journal:  J Lipid Res       Date:  2010-04-26       Impact factor: 5.922

Review 2.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 3.  Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

Authors:  Preethi Mani; Anand Rohatgi
Journal:  Curr Atheroscler Rep       Date:  2015-08       Impact factor: 5.113

Review 4.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 5.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

6.  Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

7.  Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects.

Authors:  S Nozaki; H Kashiwagi; S Yamashita; T Nakagawa; B Kostner; Y Tomiyama; A Nakata; M Ishigami; J Miyagawa; K Kameda-Takemura
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

Review 8.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

Review 9.  Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein.

Authors:  Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

Review 10.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.